Newly developed retatrutide, a twin -action medication targeting both GLP-1 and GIP receptors, is sparking considerable excitement within the medical community. Initial clinical research have demonstrated impressive reductions in overall weight and advancements in physiological markers for people with obesity . Researchers believe this novel appro